维生素D补充对甲状腺功能减退症的影响:随机对照D-Health试验
基于D-Health随机双盲安慰剂对照试验(n=21,315)分析17,851名60岁及以上澳大利亚人,维生素D组8939例、安慰剂组8912例,中位随访4.1年。维生素D补充未显著降低甲状腺功能减退症发生率(总体HR 0.89;95%CI 0.71-1.12),女性中可能有益(HR 0.78;95%CI 0.58-1.06)但需进一步研究。
要点
- 维生素D补充未显著降低总体甲状腺功能减退症发生率(HR 0.89;95%CI 0.71-1.12)。
- 女性中观察到可能有益效应(HR 0.78;95%CI 0.58-1.06),但未达统计学显著。
- 男性中无效应(HR 1.06;95%CI 0.74-1.50),性别交互作用P=0.20。
核心结论
- 维生素D补充未降低总体甲状腺功能减退症发生率,但女性中观察到的可能有益效应需进一步研究。
研究设计与样本
- 分析D-Health随机双盲安慰剂对照试验数据,该试验纳入21,315名60岁及以上澳大利亚人,每月补充60,000国际单位维生素D3。
- 主要分析纳入17,851名参与者(维生素D组8939例;安慰剂组8912例),随访自随机化后12个月开始,排除第一年内死亡或已领取左甲状腺素者。
- 甲状腺功能减退症为D-Health试验的三级结局,定义为接受左甲状腺素治疗,通过链接澳大利亚药品福利计划确定,结局为至首次左甲状腺素处方的時間。
- 采用灵活参数生存模型评估维生素D补充对甲状腺功能减退症的影响,并按年龄、性别、体重指数和预测基线维生素D状态分层分析。
主要发现
- 中位随访4.1年(四分位距4.1-4.1)期间,293例参与者发生甲状腺功能减退症(维生素D组138例[1.5%];安慰剂组155例[1.7%])。
- 维生素D补充未显著降低甲状腺功能减退症发生率(总体HR 0.89;95%CI 0.71-1.12)。
- 女性中观察到可能效应(总体HR 0.78;95%CI 0.58-1.06),男性中无效应(总体HR 1.06;95%CI 0.74-1.50;交互作用P=0.20)。
局限性
- 女性中观察到的可能有益效应需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Hypothyroidism is common, and in iodine-sufficient areas, it is primarily caused by autoimmune destruction of the thyroid gland. Observational studies have consistently shown an inverse association between serum 25-hydroxyvitamin D concentration and autoimmune diseases; however, there is a lack of evidence from randomized controlled trials to support a benefit of vitamin D supplementation, particularly for autoimmune thyroid diseases. We, therefore, aimed to assess the effect of vitamin D supplementation on the incidence of hypothyroidism. Methods: We analyzed data from the D-Health Trial (n = 21,315), a randomized double-blind placebo-controlled trial of 60,000 international units per month of supplemental vitamin D3 among Australians aged 60 years and over. Hypothyroidism, a tertiary outcome of the D-Health Trial, was defined by treatment with levothyroxine, ascertained through linkage with the Australian Pharmaceutical Benefits Scheme. The outcome was time to first prescription of levothyroxine. We began follow-up at 12 months after randomization; people who had died or who had been dispensed levothyroxine during the first year were excluded. Flexible parametric survival models were used to assess the effect of vitamin D supplementation on hypothyroidism, overall and within strata defined by age, sex, body mass index, and predicted baseline vitamin D status. Results: We included 17,851 participants in the main analysis (vitamin D = 8939; placebo = 8912). During a median follow-up of 4.1 years (interquartile range 4.1-4.1), 293 participants developed hypothyroidism (vitamin D = 138 [1.5%]; placebo = 155 [1.7%]). Vitamin D supplementation did not significantly reduce the incidence of hypothyroidism (overall hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.71-1.12). There was some suggestion of an effect in females (overall HR 0.78; CI 0.58-1.06) but not in males (overall HR 1.06; CI 0.74-1.50; p interaction 0.20). Conclusions: Vitamin D supplementation did not reduce the incidence of hypothyroidism overall; however, the possible beneficial effect observed in females warrants further investigation. Clinical Trial Registration: Australian New Zealand Clinical Trials Registry: ACTRN12613000743763.
引用
- Waterhouse M, Pham H, Rahman ST, et al. The Effect of Vitamin D Supplementation on Hypothyroidism in the Randomized Controlled D-Health Trial. Thyroid. 2023. PMID: 37698908. doi:10.1089/thy.2023.0317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。